AU2002340681B2 - PSP-94: Use for treatment of hypercalcemia and bone metastasis - Google Patents

PSP-94: Use for treatment of hypercalcemia and bone metastasis Download PDF

Info

Publication number
AU2002340681B2
AU2002340681B2 AU2002340681A AU2002340681A AU2002340681B2 AU 2002340681 B2 AU2002340681 B2 AU 2002340681B2 AU 2002340681 A AU2002340681 A AU 2002340681A AU 2002340681 A AU2002340681 A AU 2002340681A AU 2002340681 B2 AU2002340681 B2 AU 2002340681B2
Authority
AU
Australia
Prior art keywords
psp
pthrp
metastatic
cancer
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002340681A
Other languages
English (en)
Other versions
AU2002340681A1 (en
Inventor
Christopher Newman
Chandra J Panchal
Shafaat Ahmed Rabbani
Nicholas Shukeir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambrilia Biopharma Inc
Original Assignee
Ambrilia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrilia Biopharma Inc filed Critical Ambrilia Biopharma Inc
Publication of AU2002340681A1 publication Critical patent/AU2002340681A1/en
Assigned to AMBRILLA BIOPHARMA INC. reassignment AMBRILLA BIOPHARMA INC. Request for Assignment Assignors: PROCYON BIOPHARMA INC.
Assigned to AMBRILIA BIOPHARMA INC. reassignment AMBRILIA BIOPHARMA INC. Alteration of Name(s) of Applicant(s)/Patentee(s) Assignors: Ambrila Biopharma Inc.
Application granted granted Critical
Publication of AU2002340681B2 publication Critical patent/AU2002340681B2/en
Priority to AU2007246192A priority Critical patent/AU2007246192A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
AU2002340681A 2001-11-08 2002-11-08 PSP-94: Use for treatment of hypercalcemia and bone metastasis Ceased AU2002340681B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007246192A AU2007246192A1 (en) 2001-11-08 2007-12-14 PSP-94: use for treatment of hypercalcemia and bone metastasis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002361736A CA2361736A1 (en) 2001-11-08 2001-11-08 Psp 94: use for treatment of hypercalcemia and bone metastasis
CA2,361,736 2001-11-08
PCT/CA2002/001737 WO2003039576A1 (en) 2001-11-08 2002-11-08 Psp-94: use for treatment of hypercalcemia and bone metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007246192A Division AU2007246192A1 (en) 2001-11-08 2007-12-14 PSP-94: use for treatment of hypercalcemia and bone metastasis

Publications (2)

Publication Number Publication Date
AU2002340681A1 AU2002340681A1 (en) 2003-07-24
AU2002340681B2 true AU2002340681B2 (en) 2007-09-13

Family

ID=4170464

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002340681A Ceased AU2002340681B2 (en) 2001-11-08 2002-11-08 PSP-94: Use for treatment of hypercalcemia and bone metastasis

Country Status (6)

Country Link
US (1) US20030119744A1 (https=)
EP (1) EP1441756A1 (https=)
JP (1) JP2005513000A (https=)
AU (1) AU2002340681B2 (https=)
CA (1) CA2361736A1 (https=)
WO (1) WO2003039576A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050148514A1 (en) * 2003-09-26 2005-07-07 Panchal Chandra J. Method and composition for treatment of angiogenesis
CA2441695A1 (en) * 2003-09-26 2005-03-26 Unknown Regulation of matrix metalloproteinases by psp94 family members
JP2008501645A (ja) * 2004-06-01 2008-01-24 アンブリリア・バイオファーマ・インコーポレーテッド 血管新生を治療し、癌の進行および転移を予防するための方法、ならびにそのための前立腺分泌タンパク質（ｐｓｐ９４）ファミリーメンバーを含む組成物
CA2502479A1 (en) * 2004-12-01 2006-06-01 Procyon Biopharma Inc. Laminin receptor binding molecule
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2355334A1 (en) * 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
US20050026833A1 (en) * 2001-11-08 2005-02-03 Rabbani Shafaat Ahmed PSP-94: use for treatment of hypercalcemia and bone metastasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Francini et al. Cancer (2001) vol 92(6), pp 1468-1474 *
Rabbani et al. Int J Cancer (1999) vol 80(2), pp 257-264 *

Also Published As

Publication number Publication date
JP2005513000A (ja) 2005-05-12
WO2003039576A1 (en) 2003-05-15
US20030119744A1 (en) 2003-06-26
CA2361736A1 (en) 2003-05-08
EP1441756A1 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
US8551951B2 (en) Pharmaceutical preparations and methods for inhibiting tumors
US10611798B2 (en) PAR1 and PAR2 c-tail peptides and peptide mimetics
AU2002340681B2 (en) PSP-94: Use for treatment of hypercalcemia and bone metastasis
US7601801B2 (en) HLA-A24 binding cancer antigen peptide derived from livin
AU2002340681A1 (en) PSP-94: Use for treatment of hypercalcemia and bone metastasis
JPWO2018207866A1 (ja) がん治療効果の検査方法及び免疫応答誘導用組成物
US20050026833A1 (en) PSP-94: use for treatment of hypercalcemia and bone metastasis
US8252545B2 (en) Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods
AU2007246192A1 (en) PSP-94: use for treatment of hypercalcemia and bone metastasis
US20050277161A1 (en) Phosphopeptide antigens associated with MHC molecules
EP3269727B1 (en) Anti-hepatitis b virus x protein polypeptide pharmaceutical
AU765733B2 (en) HLA-A2 restraint tumor antigen peptide originating in SART-1
CA2407548A1 (en) Psp94: use for treatment of hypercalcemia and bone metastasis
US8129349B2 (en) Treatment of disease by inducing cell apoptosis
CA2143945A1 (en) A method for the detection and treatment of prostate disease
US20060052296A1 (en) Method of cell growth inhibition with agnoprotein
US7754871B2 (en) mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy
ES2351783T3 (es) Preparaciones farmacéuticas y procedimientos para la inhibición de tumores.
WO2003072031A2 (en) Treatment of disease by inducing cell apoptosis
CA2545639A1 (en) Regulation of matrix metalloproteinases by psp94 family members
HK1036996A (en) Hla-a2 restraint tumor antigen peptide originating in sart-1
CA2502479A1 (en) Laminin receptor binding molecule

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: AMBRILLA BIOPHARMA INC.

Free format text: FORMER NAME: PROCYON BIOPHARMA INC.

TH Corrigenda

Free format text: IN VOL 20, NO 42, PAGE(S) 4111 UNDER THE HEADING CHANGE OF NAMES(S) OF APPLICANT(S), SECTION 104 - 2002 UNDER THE NAME AMBRILLA BIOPHARMA INC., APPLICATION NO.2002340681, UNDER INID(71), CORRECT TO READ AMBRILA BIOPHARMA INC.

TC Change of applicant's name (sec. 104)

Owner name: AMBRILIA BIOPHARMA INC.

Free format text: FORMER NAME: AMBRILA BIOPHARMA INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired